Radiolabeled prostate specific membrane antigen inhibitors

A compound represented by formula II

• wherein:
• X and Y are each independently (CHR1)m or C(O);
• W is H, ═O—(CHR1)m—(CH2)p—, or —(CH2)p—U;
• represents a single or a double bond;
• L is —C(O)—(C1-C10)alkylene, —[C(O)—(CH(Z)d)—NH];
• NR2R3, —C(O)—(CHR1)—(CH2)p—U—, —(C5-C14)aryl-(C1-C10)alkylene, R7-benzyl, —(C5-C14)heteroaryl-(C1-C10)alkylene, —C(O)—[(CH2)p—V]n—(CH2)q—C(O)—U, [C(O)—CH(Z)d—NH]t—C(O)—(CHR1)m—(CH2)p—[U]r, —C(S)—NH-benzylene, —C(O)—NH-benzylene, —[C(O)—(CH(Z)d)—NH]s-benzylene-, or —(C1-C10)alkylene-NR4R5;
• T is selected from the group consisting of:
• H, —(C1-C10)alkylene, RC(O)—(C1-C10)alkylene, NR2R3—(C1-C10)alkylene, —(C5-C14)heteroaryl-(C1-C10)alkylene, —(C5-C14)aryl-(C1-C10)alkylene and R6—(C5-C14)heteroarylene-(C1-C10)alkylene;
• U is selected from the group consisting of:
• —OR, —COR, —(C5-C14)arylene and —NR4R);
• V is selected from the group consisting of:
• —NH—, —NR2— and —NR2R3;
• Z is —(CH2)p—COOH, —(CH2)p—(C5-C14)aryl, or —(CH2)p—NR2R3;
• R, Ra and Rb are each independently —H, —OH, —(C1-C10)alkyl, —O(C1-C10)alkyl, —NHR2, or —NR2R3;
• R1 and R′″ are each independently —H, —NH2, or —(CH2)p—U;
• R2, R3, R4, R5 and R6 are each independently H, bond, (C1-C10)alkylene, F, Cl, Br, I, C(O), C(S), —C(S)—NH-benzyl-, —C(O)—NH-benzyl-, —C(O)—(C1-C10)alkylene, —(CH2)v—NR4, —(CH2)p—NH—C(O)—(CH2)p—, —(CH2—CH2)t—NH—C(O)—(CH2)p—, —(CH2)p—COR, —(CH2)p—C(O)NH—C[(CH2)p—COR]3, —C[(CH2)p—COR]3, or —(CH2)p—(C5-C14)heteroaryl;
• R7 is —O(CH2)p—(C5-C14)heteroaryl-(CH2)p—U;
• D is
• and
• d, j, k, m, n, p, q, r, s, t and v are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
• with the proviso that where W is —(CH2)5— or —CH(NH2)—(CH2)4—, then L is not —C(O)CH2—.